---
title: "Eli Lilly's baricitinib showed near-complete scalp hair regrowth after one year of treatment in adol"
description: "Eli Lilly's baricitinib showed near-complete scalp hair regrowth after one year of treatment in adolescents with severe alopecia areata in the Phase 3 BRAVE - AA - PEDS trial"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262597587.md"
published_at: "2025-10-24T10:47:20.000Z"
---

# Eli Lilly's baricitinib showed near-complete scalp hair regrowth after one year of treatment in adol

> Eli Lilly's baricitinib showed near-complete scalp hair regrowth after one year of treatment in adolescents with severe alopecia areata in the Phase 3 BRAVE - AA - PEDS trial

Eli Lilly's baricitinib showed in the phase 3 BRAVE - AA - PEDS trial that nearly complete scalp hair regrowth can be achieved in adolescents with severe alopecia after one year of treatment

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 禮來公司聲明：Mirikizumab 在中國獲批用於治療中度至重度克羅恩病和潰瘍性結腸炎 | 禮來：Mirikizumab 在中國獲得批准用於治療中重度克羅恩病和潰瘍性結腸炎 - 公司聲明 | [Link](https://longbridge.com/en/news/275551012.md) |
| 禮來第四季度營收為 192.9 億美元，同比增長 43%。預計全年營收為 800 億至 830 億美元，市場預期為 777.1 億美元 | 禮來第四季度營收為 192.9 億美元，同比增長 43%。預計全年營收為 800 億至 830 億美元，市場預期為 777.1 億美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| 禮來在冬奧會廣告中讚美科學和體育的進步 | 禮來正在推出一項新的企業活動 “Never Over”，與 2026 年意大利冬季奧運會相結合。該活動包括一則長達一分鐘的電視廣告，展示了檔案資料和討論科學方法的旁白。它強調了禮來對科學進步的承諾與奧運運動員的奉獻之間的聯繫。該活動旨在突出 | [Link](https://longbridge.com/en/news/275193934.md) |
| Bessemer Group Inc. 收購了禮來公司 48,062 股股票 $LLY | 貝塞默集團公司（Bessemer Group Inc.）將其在禮來公司（Eli Lilly and Company）的持股比例提高了 14.5%，增持了 48,062 股，總持股量達到 380,648 股，市值為 2.904 億美元。其他機 | [Link](https://longbridge.com/en/news/274952193.md) |
| Smartleaf Asset Management LLC 購入了禮來公司 2,820 股股票 | Smartleaf Asset Management LLC 在第三季度將其在禮來公司（NYSE: LLY）的持股增加了 32.6%，額外購買了 2,820 股，總持股達到 11,467 股，價值為 833 萬美元。其他機構投資者也調整了他 | [Link](https://longbridge.com/en/news/275226320.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.